Marwan Salih AL-NIMER, Talar Ahmad MERZA

Assessment of some prescribed drugs in the management of COVID-19 on the survival function: A preliminary report from a single center in Iraq

Several medications are used to treat the patients and to control the spread of the disease. Some of these drugs proved to be harmful besides drug-drug interactions can be occurred particularly in old-age groups or patients with chronic diseases. This study aimed to investigate the effects of several drugs on the survival outcome of COVID19 patients hospitalized in a single medical center in Erbil, Iraq. 204 patients (128 men and 76 women) with COVID-19 were recruited from the West Erbil Emergency hospital between August 10 and November 20, 2020. The primary outcome measures were the survival rate during the course of illness taking into consideration the number and the generic name of prescribed drugs, the percentage of saturated blood oxygen (sPO2), and the age. A total number of sixty-four patients died. Non-survivors are characterized by having a significantly lower percentage of sPO2 and used a significantly high mean value of a number (4-5) of drugs during the course of treatment. The percentage of nonsurvivors who used fluoroquinolones was significantly higher than the corresponding percentage of survivors (37.5 vs 21.4, p=0.016). The cumulative odds ratio (> 1.0) was observed significantly (χ2= 6.286, p=0.012) in patients who used five-drug items despite the sPO2≥ 90%. We conclude that drug combinations of more than three drugs are harmful in old-age group patients, and dexamethasone, carbapenems, and fluoroquinolones should be not prescribed as empiric therapy.

PDF

___

[1] Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol. 2016; 90(16): 7415-7428.
[2] Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of Coronaviruses. Trends Microbiol. 2016; 24(6): 490-502.
[3] WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. [who.int/china/news/detail/09-01-2020- who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china]. Retrieved on 10 January 2020.
[4] Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, Bonanomi E, Cabrini L, Carlesso E, Castelli G, Cattaneo S, Cereda D, Colombo S, Coluccello A, Crescini G, Forastieri Molinari A, Foti G, Fumagalli R, Iotti GA, Langer T, Latronico N, Lorini FL, Mojoli F, Natalini G, Pessina CM, Ranieri VM, Rech R, Scudeller L, Rosano A, Storti E, Thompson BT, Tirani M, Villani PG, Pesenti A, Cecconi M; COVID-19 Lombardy ICU Network. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med. 2020; 180(10): 1345-1355.
[5] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513.
[6] Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3): 149-150.
[7] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020; 11(1): 222.
[8] Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015; 5(4): 310-315.
[9] RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020; 384 (8): 693-704.
[10] Miesbach W, Makris M. COVID-19: Coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. 2020; 26: 1076029620938149.
[11] Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with Covid-19. J Thromb Thrombolysis. 2020; 50(2): 298-301.
[12] Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, Ito F, Yamamoto T, Kawachi S, Akagawa KS, Ōmura S, Sunazuka T, Ito N, Mimaki M, Suzuki K. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019; 72(10): 759-768.
[13] Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M; Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020; 97: 396-403.
[14] Vaillancourt M, Jorth P. The unrecognized threat of secondary bacterial infections with COVID-19. mBio. 2020; 11(4): e01806-20.
[15] Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020; 51(7): 741-742.
[16] Gallacher SD, Seaton A. Meningococcal meningitis and COVID-19 co-infection. BMJ Case Rep. 2020; 13(8): e237366.
[17] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-1062.
[18] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, Zhang C, Yue J, Zhang Z, Renz H, Liu X, Xie J, Xie M, Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1): 110-118. .
[19] Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, Maecker H, Davis MM, Nguyen PK, Wu SM. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep. 2020; 22(5): 32.
[20] De Smet R, Mellaerts B, Vandewinckele H, Lybeert P, Frans E, Ombelet S, Lemahieu W, Symons R, Ho E, Frans J, Smismans A, Laurent MR. Frailty and mortality in hospitalized older adults with COVID-19: Retrospective Observational Study. J Am Med Dir Assoc. 2020; 21(7): 928-932.e1.
[21] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19): 1813-1826.
[22] Liu C, Wen Y, Wan W, Lei J, Jiang X. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol. 2021; 90: 107157.
[23] Oka S, Shiragami H, Nohgawa M. Intravascular hemolytic anemia in a patient with antibodies related to meropenem. Intern Med. 2015;54(10): 1291-1295.
[24] Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, Hermann D, Polak S. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS J. 2018; 20(3): 47.